Simtra BioPharma to Expand U.S. Manufacturing Capacity for Injectable Medicines

It's evaluating a project to design and install manufacturing lines at the site.

The new site is near Simtra's existing facility in Bloomington, Indiana.
The new site is near Simtra's existing facility in Bloomington, Indiana.
Simtra BioPharma

Simtra BioPharma Solutions, a  contract development and manufacturing (CDMO) specializing in injectable medicines, announced the purchase from Cook Group of a 65-acre property with more than 300,000 square feet of available space for expansion under-roof near its existing manufacturing facility in Bloomington, Indiana.

Simtra is evaluating a project to design and install manufacturing lines at the site, including the company's first U.S.-based commercial-scale capacity for oncology-focused injectable drug products. The facility would run isolator-based vial and prefilled syringe filling lines. Simtra's model allows for "build-to-suit" solutions that meet the unique needs of individual customers and their products.

This purchase complements other previously announced investments in the company's growth, including the $250 million construction project currently underway at Simtra's existing Bloomington manufacturing site, and the recently completed $100+ million new production building and $14 million conjugation and purification suite being built in Halle/Westfalen, Germany.

Simtra will be working closely with Monroe County, Indiana officials on a phased development plan, and the Company will share additional details in the coming weeks.

More in Operations